trending Market Intelligence /marketintelligence/en/news-insights/trending/vjTUYrPtWGBSrvBAifQnuA2 content
Log in to other products

Login to Market Intelligence Platform

 /


Looking for more?

Contact Us

Request a Demo

You're one step closer to unlocking our suite of comprehensive and robust tools.

Fill out the form so we can connect you to the right person.

  • First Name*
  • Last Name*
  • Business Email *
  • Phone *
  • Company Name *
  • City *
  • We generated a verification code for you

  • Enter verification Code here*

* Required

In This List

Gilead to pay Kyverna $17.5M upfront in autoimmune disease partnership

S&P Global Market Intelligence

Cannabis: Hashing Out a Budding Industry

Segment

IFRS 9 Impairment How It Impacts Your Corporation And How We Can Help

The Market Intelligence Platform


Gilead to pay Kyverna $17.5M upfront in autoimmune disease partnership

Gilead Sciences Inc. has signed a licensing agreement with Kyverna Therapeutics to develop T cell therapies to treat autoimmune diseases.

Kyverna will provide its synthetic T platform with a technology called synNotch, which was developed by Gilead's Kite Pharma unit.

Gilead will pay an upfront fee of $17.5 million, and Kyverna will be eligible for up to $570 million in development and commercialization milestones.

Kyverna will handle research and clinical studies, and Gilead will have an option to advance clinical development and commercialization efforts for any candidates that emerge from the partnership.